Physician profile
Uzma Iqbal
NPI 1609862457
$4,567.58
in general payments reported to CMS, 2019-2025
26 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,572 · 2020: $47.05 · 2021: $351 · 2022: $507 · 2023: $380 · 2024: $559 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,090.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $2,408.70 | 2019 | |
| Novartis Pharmaceuticals Corporation | $363.56 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.55 | 2019-2025 | Jardiance |
| Kestra Medical Technology Services, INC. | $169.48 | 2022-2024 | Assure Wcd |
| Janssen Pharmaceuticals, INC | $130.78 | 2021-2024 | Xarelto |
| Pfizer INC. | $127.13 | 2022-2024 | |
| Glaxosmithkline, LLC. | $124.71 | 2021 | |
| Astellas Pharma US INC | $111.32 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $104.39 | 2021-2023 | Verquvo |
| Irhythm Technologies, INC. | $102.85 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Edwards Lifesciences Corporation | $87.93 | 2019-2023 | Sapien 3 Ultra Resilia |
| Amgen INC. | $69.65 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $68.28 | 2019-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $60.42 | 2022-2024 | Camzyos |
| Novo Nordisk INC | $55.88 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $53.38 | 2022-2023 | |
| Alnylam Pharmaceuticals INC. | $49.80 | 2021-2025 | Amvuttra |
| Amarin Pharma, INC. | $34.48 | 2019-2021 | |
| Cvrx, INC. | $33.74 | 2023 | Barostim Neo System |
| Esperion Therapeutics, INC. | $29.40 | 2020-2021 | |
| Impulse Dynamics (USA) INC. | $28.48 | 2024 | Optimizer |
| Kiniksa Pharmaceuticals, LTD. | $28.07 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.60 | 2019-2021 | |
| Abbott Laboratories | $23.03 | 2024 | Jot Dx |
| Boston Scientific Corporation | $20.55 | 2025 | Watchman Flx |
| Inspire Medical Systems, INC. | $17.42 | 2024 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uzma Iqbal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.